A prospective observational study of patients attending a gynecological clinic and those referred to a clinic for genitourinary infections was undertaken with the purpose of evaluating the relative prevalence of non-C. albicans Candida species among Candida isolates from the vagina in different clinical settings in an area with high occurrence of vulvovaginal candidiasis. The rate of non-C. albicans Candida species was 44 5% among asymptomatic women, 19 4% among those with sporadic vaginitis and 21% among patients with chronic vaginal symptoms (p50 001 for asymptomatic vs. pooled symptomatic women). No increase in the rate of non-C. albicans Candida was observed during a period of 4 years (1995-1998) despite a 1 57-fold increase in the sales of azole antifungal agents. Unlike some previous reports we could not document an association of non-C. albicans Candida species with chronic vaginal symptoms or increased use of azole antifungal agents. The signi cantly higher rate of these yeasts in asymptomatic women is in accord with the known tendency of non-C. albicans Candida species to cause mild symptoms.
Introduction
Candida is one of the most common causes of vaginal infection [1] , and the incidence of vulvovaginal candidiasis has continued to increase during the last decade [2] . According to earlier reports C. albicans was the cause of 80-95% of cases of symptomatic fungal vulvovaginitis, whereas other Candida species, such as C. glabrata, C. parapsilosis and C. tropicalis, were responsible for the remaining cases [3, 4] . More recently, an increase in the isolation rate of non-C. albicans species, particularly C. glabrata, has been reported [5] [6] [7] [8] , a shift that was explained by a widespread use of over-thecounter drugs [9] . Other than the epidemiological importance of reporting changes in prevalence of pathogens and investigating the possible causes, documenting this new trend might have therapeutic implications, because non-C. albicans species appear to be less responsive to azole therapy than C. albicans [8, 10, 11] . We sought, therefore, to evaluate the relative prevalence of non-C. albicans Candida vaginal infections in different clinical settings in an area with high prevalence of vulvovaginal candidiasis [12] .
Materials and methods
The study population was composed of three groups of women: (a) asymptomatic women who were seen at a gynecological clinic in Bat-Yam, Israel, between 15 November 1994 and 15 June 1995 for routine check-up or for prescription of contraceptives, and who not had vulvovaginal symptoms in the preceding 6 months or more; (b) women who presented to the same clinic during the same period with acute vulvovaginal symptoms (at least one of the following: vaginal discharge, itching, burning); and (c) women referred for chronic vulvovaginal complaints to a clinic for genitourinary infections at the E. Wolfson Hospital, Holon, Israel, from January 1995 through December 1998. Holon and Bat-Yam are neighboring towns in the Tel Aviv area and have similar populations. The two clinics served both towns' citizens equally. The patients were representative of a non-promiscuous middle-class population (88% had 1 sexual partners in the preceding year 
Results
One hundred and seventy-eight patients were evaluated at the gynecological clinic. Candida species were isolated in 71 women (39 8%). The isolation rate was 33% (33/ 100) among the asymptomatic women and 48 7% (38/78) among the symptomatic patients. Isolates from 58 patients were available for species identi cation. The prevalence of non-C. albicans Candida strains was 31 0% (18/58). The 18 non-C. albicans isolates included 11 C. glabrata, three C. parapsilosis and four other species (one each of C. krusei, C. guilliermondii, C. famata and Saccharomyces cerevisiae). Of the 58 isolates, 27 belonged to asymptomatic women, 12 (44 5%) of which were non-C. albicans strains; 31 isolates were recovered from symptomatic patients, six (19 4%) of which were non-C. albicans strains ( Table 1) . The difference in the rate of non-C. albicans Candida species in the two groups was statistically signi cant (x 2 , p50 01).
During the 4-year study period, approximately 1000 patients with chronic vaginal symptoms were seen at the clinic for genitourinary infections; Candida was isolated in 110. Non-C. albicans Candida was detected in 23 (21%) of the patients: there were 12 cases of C. glabrata, four cases of C. parapsilosis, three cases of C. tropicalis, two of C. krusei and two cases involving other species (C. norvegiensis and Saccharomyces cerevisiae). In three patients, C. albicans and non-C. albicans species were isolated concomitantly, and in another ve cases they were isolated on separate occasions. The patients yielding mixed isolations were evaluated as non-C. albicans cases. When the rate of non-C. albicans Candida species in asymptomatic women was compared to that in all symptomatic patients (acute and chronic combined), the difference was highly statistically signi cant (x 2 , p50 01). Table 2 shows the annual isolation rate of non-C. albicans species in patients with chronic vaginal complaints between 1995 and 1998. The rate of isolation of non-C. albicans strains had decreased over the years; however, the difference was statistically insigni cant. Table 3 shows some epidemiological and clinical characteristics of the patients with non-C. albicans Candida and those with C. albicans. There were no statistically signi cant differences between the two groups in mean age, mean years of schooling, marital status, gravity (percentage of women that were ever pregnant and mean number of pregnancies), parity (percentage of women that had children and mean 
Discussion
The results of the present study are unique in several aspects. We have shown that in asymptomatic women the rate of non-C. albicans Candida isolation from the vagina was signi cantly higher than that in patients with vaginal symptoms. This nding should not surprise us if we consider that the typical clinical presentation of non-C. albicans Candida infections is characterized by milder symptoms than those caused by C. albicans vaginitis [Q1, [13] [14] [15] . One should thus expect non-C. albicans Candida colonization to be more often asymptomatic than C. albicans infection would be. Moreover, clinical experience has thought us that in a considerable proportion of symptomatic patients with positive vaginal smears and cultures for non-C. albicans Candida species, symptoms may persist after therapy despite laboratory eradication of the fungus, leading to the conclusion that the symptoms were unrelated to the colonization, which was in fact asymptomatic. A similar trend was described by Oriel et al. [16] in a small group of patients with C. glabrata, more than half of whom were asymptomatic. Redondo-Lopez et al. [11] reported that 42% of C. glabrata cases in their series of patient attending a vaginitis clinic were associated with symptomatic vaginitis, whereas 30% of the cases were totally asymptomatic with normal physical examination. In the remaining 27%, the role of C. glabrata in causing symptoms was unclear because of concomitant pathology. In a study conducted in the 1970s among asymptomatic women [17] , non-C. albicans fungi accounted for 27 7% of all fungal species recovered from the vagina. Although the study did not include a control group of symptomatic women, the above-reported rate of non-C. albicans spp. was markedly higher than those reported at the same period for symptomatic patients ( 6%) [15] or unselected women ( 16%) [15, 18] . We are not aware of any previously reported sound study comparing the prevalence of non-C. albicans Candida of the vagina in asymptomatic and symptomatic women. Our nding of very similar rates of non-C. albicans Candida infections in patients with sporadic vaginitis (less than three episodes in the preceding year) and in those with chronic disease challenges previous claims about the increase risk of non-C. albicans Candida infections in patients with chronic vaginitis. The association of non-C. albicans Candida infection with chronic vaginitis was evoked in a number of studies [6, 7, 13, 19] , three of which [7, 13, 19] emanated from a single center (one of these [13] being con ned to the study of C. glabrata infection). The fourth study [6] evaluated only patients with chronic vaginal symptoms and found by contrast that patients with symptoms of 4 3-year duration were somewhat more common (30%) in the C. albicans group than among patients with non-C. albicans infection (26%). In the series of Redondo-Lopez et al. [11] , only 9% of patients with C. glabrata vaginitis suffered recurrent symptomatic episodes. One should be attentive to the possibility that published data may be marred by selection bias due to the referral basis of population studied. We have overcome this obstacle by studying women from different clinical settings and various clinical presentations. The present study is to our knowledge the only one to compare a population of women with acute sporadic symptoms to a group of patients with chronic or recurrent complaints.
In contrast with previous studies [5] [6] [7] [8] , we did not nd an increase in the prevalence of non-C. albicans Candida vaginitis from 1995 to 1998. In fact, a consistent decline in the rates of non-C. albicans Candida species was observed over the study years despite an increase in azole sales in Israel during the same period. However, the sample size was small and the observed trend was statistically insigni cant. Consumption of uconazole grew 2 6-fold, that of clotrimazole 1 3-fold and that of other azoles 1 6-fold. Although the expanding use of azoles has been held responsible for the increase in rates of non-C. albicans Candida infections [9] , it apparently had no effect on the present study population. Moreover, no difference was observed in the previous use of antifungal agents between patients with non-C. albicans infection and those infected with C. albicans. The potential impact of antifungal agents might have been dissipated by the high rate of asymptomatic carriers of non-albicans strains who used these drugs markedly less than did symptomatic patients. It should also be noted that two other factors which may increase the prevalence of non-C. albicans Candida infections, namely HIV infection and over-the-counter availability of vaginal antifungal agents [1, 7, 9] , were not pertinent in our case. Our results are, thus, in accordance with those of two large multicenter studies that failed to demonstrate any increase in the prevalence of vaginitis caused by non-C. albicans species [20, 21] . Finally, we could not con rm previously reported associations of non-C. albicans Candida vaginitis with a variety of factors such as older age [13] , lower socioeconomic status [13] , use of tampons [13] and diabetes mellitus [22] .
